MDVN market selling off due to AE's. Thoughts? No position at this time but watching closely
I don't want to lighten anyone's focus on AEs. But I do think it is worthwhile to consider that patients were on enzalutamide for a duration roughly twice as long as the comparator, 11.8 vs 5.7 months.
Therefore, the % of patients with AEs deserves to be looked at with that mitigating factor in mind.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.